Continuing Ketogenic Diet Therapy in Setting of Hypercalcemia

Area of Science:

• Neurology
• Pediatrics
• Metabolic Disorders

Background:

• Hypercalcemia is a rare but severe adverse effect of ketogenic diet therapy (KDT).
• Management strategies for hypercalcemia during KDT, especially in adolescents, are not well-established.
• Maintaining KDT is crucial for seizure management in many patients.

Purpose of the Study:

• To present a case of hypercalcemia in an adolescent on long-term KDT.
• To describe the successful management of hypercalcemia without discontinuing KDT.
• To highlight the need for further research into KDT-associated hypercalcemia.

Main Methods:

• Retrospective chart analysis of a single patient.
• Patient developed hypercalcemia after 5 years of KDT for epilepsy.
• Treatment involved pamidronate and zoledronate for hypercalcemia while continuing KDT.

Main Results:

• A 16-year-old male with cerebral palsy and intractable epilepsy developed acute hypercalcemia.
• Standard treatments like hydration and calcium withdrawal were insufficient.
• Pamidronate and zoledronate effectively reduced serum calcium levels.
• Ketogenic diet therapy was successfully continued.

Conclusions:

• Hypercalcemia management in adolescent KDT patients requires specific guidelines.
• Pharmacological intervention can resolve hypercalcemia while preserving KDT.
• Further research is essential to develop standardized protocols for managing KDT-induced hypercalcemia.